Enzyme Replacement Therapy in Fabry Disease
Evaluation of the Long Term Efficacy of Enzyme Replacement Therapy in Fabry Disease
Sponsor: Mario Negri Institute for Pharmacological Research
Terminated
Difficulties in the patient's enrolment
Other terminated trials from Mario Negri Institute for Pharmacological Research
- Breast Neoplasm Female · Phase PHASE2 · Jan 2025
- Hyperkalemia · Phase PHASE3 · Nov 2024
- Fallopian Tube Cancer · Phase PHASE2 · Aug 2024
- Lung Cancer · Phase PHASE3 · Sep 2022
- Open Angle Glaucoma · Phase NA · Apr 2022
See all terminations from Mario Negri Institute for Pharmacological Research
Other Fabry Disease trials with similar outcome
Listed as NCT00149318, this observational or N/A phase trial focuses on Fabry Disease and remains terminated or withdrawn. Sponsored by Mario Negri Institute for Pharmacological Research, it has been updated 10 times since 2002, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Dec 2021 — Jul 2024 [monthly]
Terminated
-
Jan 2021 — Dec 2021 [monthly]
Terminated
-
Nov 2020 — Jan 2021 [monthly]
Terminated
▶ Show 5 earlier versions
-
Jun 2018 — Nov 2020 [monthly]
Terminated
-
May 2018 — Jun 2018 [monthly]
Terminated
-
Apr 2018 — May 2018 [monthly]
Terminated
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Dec 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mario Negri Institute for Pharmacological Research
For direct contact, visit the study record on ClinicalTrials.gov .